AMSTERDAM, Netherlands, June 19 /PRNewswire/ --
Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan 406. The Grand Opening ceremony was officiated by Dr. Rene Bernards, Chief Scientific Officer at Agendia and the Honourable Director General Mrs. R.M. Bergkamp, on behalf of the Honourable Mrs. Maria van der Hoeven, Minster of Economic Affairs for The Netherlands.
"Agendia has a distinguished history of providing exceptional high quality diagnostic testing services that provide valuable information for cancer patients and the physicians who treat them," said Dr. Bernhard Sixt, Agendia's president & chief executive officer (CEO). "The expanded capacity of our laboratories at our new location will allow us to meet the growing worldwide demand for our clinical services as we expand into major markets, enhancing the company's ability to serve the healthcare community."
The new facilities offer 13,000 square feet of laboratory and office space that will support the company's molecular diagnostic cancer testing services and research activities.
"Additionally, this move proves our ability to replicate our FDA-cleared and CLIA-certified laboratory in a new location in just 4 months," said Dr. Jan Groen, vice president and chief operating officer (COO) at Agendia. "The increased laboratory space will also allow the company to expand our research and product development capabilities to enhance commercialization of emerging diagnostic discoveries in cancer."
Currently, Agendia offers three test services through its expanded laboratories, including MammaPrint(R), based on the Amsterdam 70-gene profile that indicates risk of recurrence for breast cancer tumors and the first in vitro diagnostic multi index variant assay (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA), and CupPrint(R), which identifies the origin of metastases with unknown primary tumors (Cancer of Unknown Primary).
Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test -- MammaPrint(R) -- that predicts the risk of breast cancer recurrence. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology. For more information on Agendia, please visit www.agendia.com.
* CupPrint(R) is based on a license to the TUO database of AviaraDx
For Agendia - EU & non-U.S.-based Media: Dr. Bernhard Sixt President and Chief Executive Officer Agendia +31-204621520 firstname.lastname@example.org For Agendia - U.S. Media: Kelly Connor Vice President Ogilvy Public Relations Worldwide +1-212-880-5328 Office +1-609-221-5785 Mobile Kelly.connor@ogilvypr.
Web site: http://www.agendia.com
For Agendia - EU & non-U.S.-based Media - Dr. Bernhard Sixt, President and Chief Executive Officer of Agendia, +31-204621520, email@example.com, or For Agendia - U.S. Media - Kelly Connor, Vice President of Ogilvy Public Relations Worldwide, Office, +1-212-880-5328, Mobile, +1-609-221-5785, Kelly.firstname.lastname@example.org